Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.32 |
| ▸ | WNT1 | P04628 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23213563 | 0.78 | CCNC (0.38) | PDE10AJAK2JAK1TP53MDM2 | |
| SCHEMBL23239922 | 0.77 | PDE10A (0.42) | PDE10AJAK2JAK1METTL3PDE7B | |
| SCHEMBL23240205 | 0.76 | POLB (0.41) | JAK2JAK1TP53CCNCCDK8 | |
| SCHEMBL23214235 | 0.74 | PDE10A (0.41) | PDE10AJAK2JAK1PDE7BCCNC | |
| SCHEMBL23213534 | 0.74 | PDE10A (0.36) | PDE10AJAK2JAK1TP53MDM2 | |
| SCHEMBL26739655 | 0.73 | PDE10A (0.40) | PDE10AJAK2JAK1PDE7BEZH2 | |
| SCHEMBL23213567 | 0.72 | PDE10A (0.38) | PDE10APDE7BPDE1B | |
| SCHEMBL26090232 | 0.69 | CNR1 (0.39) | PDE10AJAK2JAK1KIF11METTL3 | |
| SCHEMBL26086965 | 0.65 | PDE10A (0.40) | PDE10APDE7BEZH2WNT1GSK3B | |
| SCHEMBL22425610 | 0.64 | TLR7 (0.43) | PDE10AJAK2JAK1METTL3PDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | PDE10A 1199/4885JAK2 4103/4885JAK1 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.